Abbott Laboratories (ABT) Stock Price & Analysis
Market: NYSE • Sector: Healthcare • Industry: Medical - Devices
Abbott Laboratories (ABT) Profile & Business Summary
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Key Information
| Ticker | ABT |
|---|---|
| Exchange | NYSE |
| Official Site | https://www.abbott.com |
Market Trend Overview for ABT
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-11-17 (ET)
As of 2026-11-17, ABT is showing signs of slowing down. Over the longer term, the trend remains bearish.
ABT last closed at 104.71. The price is about 1.2 ATR below its recent average price (107.99), and the market is currently in a trend that may be losing strength. Price at 104.71 is near light support around 104.20. Momentum may slow, while light resistance sits near 105.24. View Support & Resistance from Options
Short-term strength is developing against a weaker long-term trend, which increases the risk of downside reversals.
Trend score: 45 out of 100. Overall alignment is unclear. The market is currently in a late-stage trend that may be losing strength. The longer-term trend is still negative, but short-term signals are not yet confirming it.
A key downside risk boundary is near 98.01. If price falls below this area, the current structure would likely weaken further.
On 2026-11-17, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
Closing activity showed limited conviction and did not suggest strong overnight positioning.
The model stays neutral because the setup is not clear enough to justify a directional deployment.
The model does not deploy this setup because predictability is still too low and price is still close to a gamma transition zone. Predictability is 25%, agreement is 65%, and reversal risk is 28%.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This estimate uses 1-minute price, volume, and VWAP data from the last 55 trading days, with turnover-based decay. The sample period is 2026-09-01 to 2026-11-17. The current price is 104.71, 0.10% above the estimated average cost of 104.60. An estimated 60.1% of recent positioning is below the current price, while 39.4% is above it. The peak-density price is 98.40. The largest concentrated cost region is 101.67 to 104.98 and contains 35.8% of the estimated distribution. The current price is within the 101.67 to 104.98 cost region. The nearest region below the current price is 100.77 to 101.38. The nearest region above the current price is 105.12 to 105.23.
Short Interest & Covering Risk for ABT
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is well above normal levels, increasing the risk of forced covering and sudden price moves. (Historical percentile: 79%)
Structure Analysis
ABT Short positioning looks normal. Current days to cover is 1.9 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves. No meaningful structural fragility is currently detected (Fragility Score 13/100, DTC percentile 18%) with short positioning continuing to expand.
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
In the latest reporting period, short interest continues to increase. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-10-30 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.